Is AbbVie Inc. (ABBV) the Best Pharma Stock to Buy for Long Term Growth?
We recently published a list of . In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against other best pharma stocks to buy for long term growth.
With big American pharmaceutical corporations always searching for medications in China, the US pharmaceutical industry is going through a unique trend never seen before. About 30% of Big Pharma acquisitions involving at least $50 million upfront in 2024 involved Chinese corporations, according to DealForma statistics, as reported by CNBC. This was an increase from 20% the previous year and nearly 0% just five years before.
Experts cite several causes for this tendency. Some people think that Chinese pharmaceutical firms are drawing notice due to their sophisticated development skills, which enable them to produce potent compounds in large quantities. In addition to being able to start testing on human subjects more quickly, these Chinese companies can charge a lower price for these medications than the US. Buyers have developed a business strategy that enables them to import medicines through licensing agreements, according to CNBC. The dearth of venture capital in China is additional pressure on biotech companies to enter these agreements.
Experts think this situation is here to stay, even though there are several possible causes for this tendency. Although the US pharmaceutical industry is expected to be impacted, it is uncertain how these effects would manifest. If big pharmaceutical companies find a good Chinese drug at a low price, some experts think it may destroy American startups; others think the competition would benefit the sector. Tim Opler, a managing director in Stifel's global healthcare group, stated the following regarding the circumstances:
'It's kind of a watershed moment where the pharma industry is like, 'We don't really need to buy U.S. biotechs necessarily. We will if it makes sense, but we can buy perfectly good biotech assets through licensing deals with Chinese companies.'
Emily Field, Head of European Pharma Research at Barclays, spoke to CNBC on February 20 about the performance of obesity medications, the effects of US tariffs, and the dynamics of the pharmaceutical industry. According to her, at least in the first half of this year, the industry might not perform poorly. The effectiveness of obesity medications is still up for debate, though, as leading companies in the field have shown inconsistent results in the past.
Speaking about the tariffs, she stated that since some businesses assemble their products in the US after producing them overseas, their implementation raises several unanswered questions for the pharmaceutical industry. These businesses, therefore, have relatively low manufacturing costs, which is an important factor to take into account when assessing the effects of tariffs. She thought that these businesses could easily absorb the higher expense of the tariffs. The topic hasn't come up much on earnings calls this quarter, and the market is nearing the end of the reporting season.
For this article, we screened for companies that operate in the pharmaceutical industry. From that list, we identified stocks that have achieved positive revenue growth over the past five years. Then, we picked companies with a 5-year revenue growth of 10% and ranked the top 10 based on hedge fund sentiment as of Q4 2024, as per Insider Monkey's database.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
A pharmacist handing out a pharmaceutical drug to a patient in a drug store or chemist.
Number of Hedge Fund Holders: 85
AbbVie Inc. (NYSE:ABBV) is a research-based pharmaceutical company that develops and sells products to treat chronic diseases in oncology, gastroenterology, rheumatology, dermatology, virology, and various other serious health conditions.
In addition to having solid fundamentals, AbbVie Inc. (NYSE:ABBV) made $15.1 billion in fiscal Q4 2024, which was 5.6% higher than analysts had predicted. The company's ex-Humira platform, a group of medications in its pharmaceutical portfolio, was credited with this expansion. The platform increased sales by over 18% throughout the course of the year, and in fiscal Q4 2024, revenue growth accelerated to 22%.
Because of its two popular medications, Skyrizi and Rinvoq, analysts are upbeat about AbbVie Inc. (NYSE:ABBV)'s growth. As one of the best pharmaceutical stocks, the yearly sales of these medications—which treat inflammatory bowel disorders, psoriatic illnesses, rheumatology, and dermatology—are expected to surpass $27 billion by 2027. In addition, the company declared a 5.8% dividend increase that would take effect in February 2025, carrying on the company's 12-year dividend growth pattern.
said the following about AbbVie Inc. (NYSE:ABBV) in its Q3 2024:
'US biopharma/biotech companies topped the health care sector, with the majority of holdings posting returns over 10%. AbbVie Inc. (NYSE:ABBV) showed positive top-line growth from its immunosuppressive drugs, Skyrizi and Rinvoq. Abbvie's management continues to work through the loss of exclusivity from Humira, switching patients to Skyrizi or Rinvoq rather than Humira biosimilars.'
Overall, ABBV ranks 4th on our list of best pharma stocks to buy for long term growth. While we acknowledge the potential of pharmaceutical companies, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than ABBV but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock.
READ NEXT: and .
Disclosure: None. This article is originally published at .
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
7 minutes ago
- Forbes
Trump Says He'll ‘Probably' Extend TikTok Sale Deadline This Week
President Donald Trump on Tuesday suggested he would 'probably' extend a deadline for ByteDance, TikTok's China-based owners, to divest the social media app before Thursday, marking what would be his third delay after an earlier deal fell through. An order to keep TikTok operational in the U.S. for another 75 days was signed by Trump in April. Trump told reporters on Air Force One he would 'probably' extend a June 19 deadline for ByteDance to divest from TikTok or sell its assets to an American firm, adding, 'Probably have to get China approval, but I think we'll get it.' Another extension would be Trump's third delaying a forced sale or divestment of TikTok, following earlier orders pushing back the deadline on Jan. 20 and April 4, when a deal was reportedly in place for TikTok's operations to be spun off into a new U.S.-based company before Trump's 'Liberation Day' tariffs derailed the talks. Trump told NBC News last month he would 'like to see [a deal] done' for TikTok, adding he had a 'little sweet spot in my heart' for the social media platform and he would be 'willing to give it [the deadline] an extension' if needed. How long Trump would delay TikTok's deadline. Both extensions in January and April stalled a ban on TikTok by 75 days. Several companies have emerged as potential suitors for TikTok's assets, including Amazon, Oracle and Microsoft. Amazon's bid for TikTok would include the entire company, unnamed people familiar with the offer told the New York Times, though some parties involved in the talks 'do not appear to be taking Amazon's bid seriously.' AppLovin reportedly made an offer for TikTok and spoke with billionaire Steve Wynn about backing the deal, after the company told the Trump administration it could address national security concerns about the app if it held ownership. The White House previously spoke with Oracle about a deal that would give the company oversight of TikTok's U.S. data, Politico reported. Trump has also named Microsoft as a possible buyer while saying he hoped there would be a 'bidding war' for TikTok. Legislation requiring TikTok to sell itself to an American company or be banned in the U.S. was signed under President Joe Biden last year. That law followed growing bipartisan national security concerns about the app in recent years, after reports claimed China relied on TikTok's U.S. data to spy on Americans. Forbes previously reported the app spied on journalists, mishandled advertiser data and stored financial data of some creators in China, though ByteDance has denied claims user privacy was compromised. Trump issued an executive order in January shortly after he took office, though the app briefly went dark for U.S. users.
Yahoo
8 minutes ago
- Yahoo
ARK Invest Offloads Over $50M in Circle Shares as Stock Extends Rally
Cathie Wood's ARK Invest trimmed its holdings on its sizable Circle (CRCL) position Monday, selling $51.8 million worth of shares, as the stablecoin issuer's stock extended its rally. ARK sold a total of 342,658 shares across three of its actively managed exchange-traded funds (ETFs), according to a daily email. The ARK Innovation ETF (ARKK) offloaded 196,367 shares, ARKW sold 92,310 and ARKF trimmed 53,981. Circle, the issuer of the USDC stablecoin, rose 13% on the day, closing Monday in New York at $151.06. It has gained every day but two since it listed on June 5. The shares have climbed almost fivefold from their IPO price of $31. ARK bought $373 million worth of Circle on its first day of trading on the NYSE. Wood's fund also recently trimmed positions in other crypto-linked firms like Coinbase (COIN) and Robinhood (HOOD). Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
10 minutes ago
- Yahoo
Tax Bill Lacks Votes as Senate Aims for Deals on SALT, Medicaid
(Bloomberg) -- Republican leaders are aiming for quick negotiations over needed changes to the newly unveiled Senate tax bill which lacks the votes to secure majorities in both chambers as written. Security Concerns Hit Some of the World's 'Most Livable Cities' As Part of a $45 Billion Push, ICE Prepares for a Vast Expansion of Detention Space As American Architects Gather in Boston, Retrofits Are All the Rage How E-Scooters Conquered (Most of) Europe Taser-Maker Axon Triggers a NIMBY Backlash in its Hometown The prospect of prolonged talks with holdouts in both the conservative and moderate wings of the party threaten Senate Majority Leader John Thune's goal of passing President Donald Trump's tax-cut legislation by July 4. The Senate bill makes much more aggressive cuts to Medicaid spending than the version the House passed last month, an aspect that is already drawing pushback from moderate Republicans and lawmakers concerned about the political ramifications of restricting health benefits for their constituents. The Senate bill takes a hardline stance against raising the $10,000 cap on the state and local tax deduction, earning it an immediate thumbs-down from a faction of New York, New Jersey and California House members who have threatened to block the bill if it doesn't include the $40,000 SALT cap deal they struck with House Speaker Mike Johnson. Generous tax breaks for tips, overtime and pass-through businesses were also scaled back to reduce the price tag of the bill. Even still, conservatives say they aren't satisfied with these efforts to reduce the overall cost and are plotting to delay a planned Senate vote next week to August. 'This is just the opening shot,' said Texas Senator John Cornyn, a leadership ally, adding that many Republicans just saw the bill for the first time on Monday. Earlier: Harvard Wins Reprieve, SALT Stalls: Tax Bill Winners and Losers The Senate can only pass the bill if a minimum of 50 out of 53 Republican senators vote for the measure and Vice President JD Vance breaks the tie. There are already more than three Republican senators who have said they have problems with the bill. 'This bill needs a lot of work,' Missouri Senator Josh Hawley said after learning the bill restricts a tax on Medicaid providers, a move that would reduce reimbursements to states and he says would mean the closure of rural hospitals. Senators Susan Collins of Maine, Lisa Murkowski of Alaska and Jim Justice of West Virginia had already objected to the less stringent Medicaid cuts in the House bill. They are likely to prove a challenge to passing the Senate bill. A group of moderates who advocate for clean energy tax breaks, including North Carolina's Thom Tillis and Utah's John Curtis said they are still studying the bill and suggested they may need more tweaks to lengthen the phaseout of tax credits for renewable energy. Conservative Demands Wisconsin Senator Ron Johnson said he is a hard 'no' on the proposed bill both because he wants steeper spending cuts and because the Senate draft scales back a proposed 23% tax deduction for pass-through business income to 20%. 'I'm confident enough that we have a group of senators that will delay this until at least the August recess so we can look at this,' Johnson said Tuesday on CNBC. Johnson counts Florida's Rick Scott, Utah's Mike Lee and Kentucky's Rand Paul in his camp of bill opponents. Scott has also said he wants more spending cuts. Paul said Tuesday he opposes the bill if it includes a debt ceiling increase. Senate leaders want to raise the debt ceiling by $5 trillion so that Congress does not have to deal with the issue again before the 2026 midterm elections. 'I can't vote to raise the debt ceiling $5 trillion because really what that means is we're going to get more of the same,' Paul said Tuesday on Fox Business. SALT Debate The Senate bill has a placeholder of $10,000 cap on the SALT deduction, setting up a negotiation with the House which passed a $40,000 cap. The inclusion of the $10,000 cap drew howls of protest from a group of swing-district House Republicans for whom SALT is a top political priority. New York Representative Nicole Malliotakis described it as 'a slap in the face to the Republican districts that delivered our majority and trifecta.' Thune has said that he believes a compromise between the two positions will be found and Tillis has said the Senate is mulling accepting a $30,000 cap in the end, something initially proposed by House GOP leaders before SALT-focused members negotiated an increase. Ken Griffin on Trump, Harvard and Why Novice Investors Won't Beat the Pros How a Tiny Middleman Could Access Two-Factor Login Codes From Tech Giants American Mid: Hampton Inn's Good-Enough Formula for World Domination The Spying Scandal Rocking the World of HR Software US Allies and Adversaries Are Dodging Trump's Tariff Threats ©2025 Bloomberg L.P.
